Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pain Ease is a topical vapocoolant spray developed and manufactured by the Gebauer Company. It is a non-invasive analgesic composed of a 95:5 ratio of 1,1,1,3,3-pentafluoropropane and 1,1,1,2-tetrafluoroethane. The product's mechanism of action involves rapid evaporation upon contact with the skin, which induces immediate cooling and produces transient local anesthesia within seconds. It is primarily indicated for the reduction of procedural pain associated with minor surgical procedures, intravenous (IV) cannulation, and venipuncture, particularly in pediatric patients. Unlike systemic analgesics or topical gels that require significant onset time, Pain Ease provides localized, temporary relief almost instantly and is classified as a medical device-adjacent pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pain Ease.